Core Viewpoint - The company, Shijiazhuang Pharmaceutical Group, announced the sale of a 30.0704% stake in Beijing Guoxin Huijin Co., Ltd. for RMB 230 million, aiming to optimize resource allocation and focus on core business operations [1] Group 1 - The seller, Shijiazhuang Pharmaceutical Innovation Co., Ltd., is a non-wholly owned subsidiary of the company [1] - The transaction is expected to enhance the seller's financial structure and reduce operational risks [1] - The target company primarily operates in the full media communication business, which is not part of the seller's core operations [1] Group 2 - The completion of the sale will result in the seller and the group no longer holding any equity in the target company [1] - The decision to sell was based on a comprehensive assessment of the seller's actual development status [1] - This move is anticipated to facilitate high-quality development for the seller and benefit the overall group [1]
石药集团(01093)：附属拟出售北京国新汇金30.0704%股权